|
Sponsored by Sage Therapeutics, Inc., and Biogen Inc.
|
|
|
|
|
Indicated for adults with postpartum depression (PPD)
|
|
|
|
Discover a groundbreaking 14-day treatment course for postpartum depression1
|
|
|
IMPORTANT SAFETY INFORMATION
|
|
WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES
|
|
ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects.
Advise patients not to drive or engage in other potentially hazardous activities until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence, or the degree of driving impairment caused by ZURZUVAE.
|
|
|
Please see additional Important Safety Information below.
|
|
|
|
|
|
|
|
In our work, we often connect with patients during some of the most challenging times, especially those dealing with the mental and physical changes that may come with postpartum depression (PPD). I encourage you to take a closer look at ZURZUVAE® (zuranolone), a once daily, oral 14-day treatment option specifically indicated for adults with PPD. It’s inspiring to see a novel approach that may be an option when caring for your patients with PPD.1,2
[Trisha Joseph, PMHNP-BC]
Compensated by Sage Therapeutics and Biogen.
|
|
|
|
|
|
|
|
Based on a ZURZUVAE 50 mg 6-week study of a 14-day treatment course with follow-up through Day 45. Patients met DSM-5 criteria for a major depressive episode with symptom onset in the third trimester or within 4 weeks of delivery and had a baseline HAMD-17 total score ≥26. Primary endpoint: Change from baseline in HAMD-17 total score at Day 15 for ZURZUVAE (N=98) vs placebo (N=97) (–15.6 ZURZUVAE vs –11.6 placebo; p=0.001). A key secondary endpoint: Change from baseline in HAMD-17 total score at Day 3 (–9.5 ZURZUVAE vs –6.1 placebo; p=0.001).1,2
|
|
|
IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS
Impaired Ability to Drive or Engage in Other Potentially Hazardous Activities
|
|
•
|
ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects
|
|
•
|
Advise patients not to drive a motor vehicle or engage in other potentially hazardous activities requiring complete mental alertness, such as operating machinery, until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence or the degree of driving impairment caused by ZURZUVAE
|
|
|
Central Nervous System Depressant Effects
|
|
•
|
ZURZUVAE can cause CNS depressant effects such as somnolence and confusion
|
|
•
|
Somnolence developed in 36% of patients who received ZURZUVAE (50 mg) and in 6% of patients who received placebo daily. Some ZURZUVAE-treated patients developed confusional state. One of these cases was severe, and was also associated with somnolence, dizziness, and gait disturbance
|
|
•
|
A higher percentage of ZURZUVAE-treated patients, compared to placebo-treated patients, experienced somnolence, dizziness, or confusion that required dosage reduction, interruption, or discontinuation
|
|
•
|
Because ZURZUVAE can cause CNS depressant effects, patients may be at higher risk of falls
|
|
•
|
Other CNS depressants such as alcohol, benzodiazepines, opioids, tricyclic antidepressants, or drugs that increase zuranolone concentration, may increase impairment of psychomotor performance or CNS depressant effects such as somnolence, cognitive impairment, and the risk of respiratory depression in ZURZUVAE-treated patients
|
|
•
|
To reduce the risk of CNS depressant effects and/or mitigate CNS
depressant effects that occurs with ZURZUVAE treatment:
|
|
|
–
|
If patients develop CNS depressant effects, consider dosage reduction or discontinuation of ZURZUVAE
|
|
–
|
If use with another CNS depressant is unavoidable, consider dosage reduction
|
|
–
|
Reduce the ZURZUVAE dosage in patients taking strong CYP3A4 inhibitors
|
|
|
Suicidal Thoughts and Behavior
|
|
•
|
In pooled analyses of placebo-controlled trials of chronically administered antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with major depressive disorder (MDD)
|
|
•
|
ZURZUVAE does not directly affect monoaminergic systems. Consider changing the therapeutic regimen, including discontinuing ZURZUVAE, in patients whose depression becomes worse or who experience emergent suicidal thoughts and behaviors
|
|
|
Embryo-fetal Toxicity
|
|
•
|
Based on findings from animal studies, ZURZUVAE may cause fetal harm when administered to a pregnant woman
|
|
•
|
Advise a pregnant woman of the potential risk to an infant exposed to ZURZUVAE in utero. Advise females of reproductive potential to use effective contraception during treatment with ZURZUVAE and for one week after the final dose
|
|
|
ADVERSE REACTIONS
|
|
•
|
The most common adverse reactions (≥5% and greater than placebo) in ZURZUVAE-treated patients were somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection
|
|
|
DRUG INTERACTIONS
|
|
CNS Depressant Drugs and Alcohol
|
|
•
|
Caution should be used when ZURZUVAE is administered in combination with other CNS drugs or alcohol. If use with another CNS depressant is unavoidable, consider dosage reduction
|
|
|
Strong CYP3A4 Inhibitors
|
|
•
|
Reduce the ZURZUVAE dosage when used with a strong CYP3A4 inhibitor
|
|
|
CYP3A4 Inducers
|
|
•
|
Avoid concomitant use of ZURZUVAE with CYP3A4 inducers
|
|
|
USE IN SPECIFIC POPULATIONS
|
|
Pregnancy
|
|
•
|
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including ZURZUVAE, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/
|
|
•
|
Based on findings from animal studies, ZURZUVAE may cause fetal harm. Advise pregnant women of the potential risk to a fetus. Available data on ZURZUVAE use in pregnant women from the clinical development program are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
|
|
|
Lactation
|
|
•
|
Available data from a clinical lactation study in 14 women indicate that zuranolone is present in low levels in human milk. There are no data on the effects of zuranolone on a breastfed infant and limited data on the effects on milk production
|
|
•
|
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZURZUVAE and any potential adverse effects on the breastfed child from ZURZUVAE or from the underlying maternal condition
|
|
|
Hepatic Impairment
|
|
•
|
The recommended ZURZUVAE dosage in patients with severe hepatic impairment (Child-Pugh C) is lower than patients with normal hepatic function
|
|
|
Renal Impairment
|
|
•
|
The recommended ZURZUVAE dosage in patients with moderate and severe renal impairment is lower than those with normal renal function
|
|
|
DRUG ABUSE AND DEPENDENCE
|
|
•
|
ZURZUVAE contains zuranolone, a Schedule IV controlled substance
|
|
•
|
Zuranolone has abuse potential with associated risks of misuse, abuse, and substance use disorder including addiction
|
|
•
|
ZURZUVAE may produce physical dependence
|
|
|
INDICATION
|
|
ZURZUVAE is indicated for the treatment of postpartum depression (PPD) in adults.
Please see full Prescribing Information, including Boxed Warning.
|
|
|
|
Discover what’s possible for your adult patients with PPD
|
|
|
|
|
References: 1. ZURZUVAE Prescribing Information. Cambridge, MA: Biogen and Sage
Therapeutics, Inc. 2. Deligiannidis KM, Meltzer-Brody S, Maximos S, et al. Zuranolone for the
Treatment of Postpartum Depression. Am J Psych. 2023;180(9):668-675.
|
|
|
|
Privacy Policy | Terms & Conditions
|
©2025 Sage Therapeutics. All rights reserved.
55 Cambridge Parkway, Cambridge, MA 02142
|
©2025 Biogen. All rights reserved.
225 Binney Street, Cambridge, MA 02142 | 1‑844‑987‑9882
|
|
Pricing Disclosures for Prescribers
|
SAGE THERAPEUTICS, the SAGE THERAPEUTICS logo, and ZURZUVAE are registered trademarks of Sage Therapeutics, Inc. BIOGEN and the BIOGEN logo are registered trademarks of Biogen Inc. The ZURZUVAE logo is a trademark of Sage Therapeutics, Inc. All other trademarks referenced herein are the property of their respective owners.
ZUR-US-1377 08/25
|
|
|
| . |
| . |
|
|
